Entrada Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Thank you, and good morning.
Thank you for joining us. I'm Paul Choi, and I covered this midcap biotech sector here at Goldman Sachs. Joining us here at the Goldman Sachs Global Healthcare Conference is Entrada.
Before we begin, I'm required to make some certain disclosures. These disclosures pertain to investment banking and other relationships that we may have with companies discussed here at the conference.
For anyone listening or who are clients at the firm attending, these disclosures are available to you on our research portal. We are prepared to read them aloud, but they are available through our Goldman Sachs research.
And with that, it's our pleasure to have Entrada here. And maybe what we'll do is start it at a high level with Tapal here and maybe talk about for those who are new to the Entrada story or maybe the DMD space, maybe walk us through what is the EEV platform and what, I guess, in the early or preclinical data has made you excited about its potential.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
